International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 597-604 , 1 October 2008

The Observed Variance Between Predicted and Measured Radiation Dose in Breast and Prostate Patients Utilizing an In Vivo Dosimeter

  • Charles W. Scarantino, M.D., Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • Department of Radiation, Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA
    • Corresponding Author InformationReprint requests to: Charles W. Scarantino M.D., Ph.D., Department of Radiation Oncology, Rex Cancer Center, 4420 Lake Boone Trail, Raleigh, NC 27607. Tel: (919) 784-3018; Fax: (919) 783-0737
    • ,
  • Bradley R. Prestidge, M.D.

      Affiliations

    • Texas Cancer Clinic, San Antonio, TX
    • ,
  • Mitchel S. Anscher, M.D.

      Affiliations

    • Department of Radiation Oncology, Rex Cancer Center, Raleigh, NC
    • ,
  • Carolyn R. Ferree, M.D.

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Bowman Gray Campus, Winston-Salem, NC
    • ,
  • William T. Kearns, M.S.

      Affiliations

    • Department of Radiation Oncology, Wake Forest University, Bowman Gray Campus, Winston-Salem, NC
    • ,
  • Robert D. Black, Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • ,
  • Natasha G. Bolick, M.S.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC
    • ,
  • Gloria P. Beyer, Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC

Received 17 December 2007 ,Revised 27 May 2008 ,Accepted 30 May 2008.

References 

  1. Byrne TE. A review of prostate motion with consideration for the treatment of prostate cancer. Med Dosim. 2005;30:155–161
  2. Scarbrough TJ, Golden NM, Ting JY, et al. Comparison of ultrasound and implanted seed marker prostate localization methods: Implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:378–387
  3. Turner SL, Swindell R, Bowl N, et al. Bladder movement during radiation therapy for bladder cancer: Implications for treatment planning. Int J Radiat Oncol Biol Phys. 1997;39:355–360
  4. Lebesque JV, Bruce AM, Kroes APG, et al. Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys. 1995;33:1109–1119
  5. Buchali A, Koswig S, Dinges S, et al. Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynecological cancer. Radiother Oncol. 1999;52:29–34
  6. Nederveen A, van der Heide UA, Dehnad H, et al. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys. 2002;53:206–214
  7. Balter J, Sandler HM, Lam K, et al. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys. 1995;31:113–118
  8. Britton KR,Takai Y, Mitsuya M, et al. Evaluation of inter and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiat Med. 2005;23:14–24
  9. Ross CS, Hussey DH, Pennington EC, et al. Analysis of movement of intrathoracic neoplasms using ultrafast computerized tomography. Int J Radiat Oncol Biol Phys. 1990;18:671–677
  10. Weiss PH, Baker JM, Potchen EJ. Assessment of hepatic respiratory excursion. J Nucl Med. 1972;13:758–759
  11. Suramo I, Päivänsalo M, Myllyla V. Cranio-caudal movements of the liver pancreas and kidneys in respiration. Acta Radiol Diag. 1984;25:129–131
  12. Vigneault E, Pouliot J, Laverdière J, et al. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: A clinical study. Int J Radiat Oncol Biol Phys. 1997;37:205–212
  13. Padhani A, Khoo VS, Suckling J, et al. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys. 1999;44:525–533
  14. Ghilezan MJ, Jaffray DA, Siewerdsen JH, et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005;62:406–417
  15. Scarantino CW, Rini CJ, Aquino M, et al. Initial clinical results of an in vivo dosimeter during external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:606–613
  16. Black RD, Scarantino CW, Mann GG, et al. An analysis of an implantable dosimeter system for external beam therapy. Int J Radiat Oncol Biol Phys. 2005;63:290–300
  17. Beddar AS, Salehpour M, Briere TM, et al. Preliminary evaluation of implantable MOSFET radiation dosimeters. Phys Med Biol. 2005;50:141–149
  18. Beyer GP, Mann G, Pursley J, et al. An implantable MOSFET dosimeter for the measurement of radiation dose in tissue during cancer therapy. IEEE J. 2008;8:38–51
  19. Scarantino CW, Ruslander DM, Rini CJ, et al. An implantable radiation dosimeter for use in external beam radiation therapy. Med Phys. 2004;31:2658
  20. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47
  21. Hayne D, Johnson U, D'Souza D, et al. Anorectal irradiation in pelvic radiotherapy: An assessment using in-vivo dosimetry. Clin Oncol (R Coll Radiol). 2001;13:126–129
  22. Weber DC, Nouet P, Kurtz JM, et al. Assessment of target dose delivery in anal cancer using in vivo thermoluminescent dosimetry. Radiother Oncol. 2001;59:39–43
  23. Wertz H, Boda-Heggemann J, Walter C, et al. Image guided in vivo dosimetry for quality assurance of IMRT treatment for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:288–295
  24. Kupelian P, Willoughby T, Mahadevan A, et al. Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1088–1098
  25. Litzenberg DW, Balter JM, Hadley SW, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:528–534
  26. Langen KM, Zhang Y, Andrews RD, et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys. 2005;62:1517–1524
  27. Yue NJ, Li X, Beriwal S, et al. The intrafraction motion induced dosimetric impacts in breast 3D radiation treatment: A 4DCT based study. Med Phys. 2007;34:2789–2800
  28. Beyer GP, Scarantino CW, Prestidge BR, et al. Technical evaluation of radiation dose delivered in prostate patients as measured by an implantable MOSFET dosimeter. Int J Radiat Oncol Biol Phys. 2007;69:925–935
  29. Lattanzi J, Mc Neeley S, Pinover W, et al. A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys. 1999;43:719–723
  30. Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:635–644
  31. Shukovsky LJ. Dose, time, volume relationships in squamous cell carcinoma of the supraglottic larynx. Am J Roent Rad Ther Nucl Med. 1970;108:27–29
  32. Stewart JF, Jackson AW. The steepness of the dose response curve for tumor and normal tissue injury. Laryngoscope. 1975;85:1107–1111
  33. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res. 1966;26:1221–1224
  34. Hellman S. Improving the therapeutic index in breast cancer treatment. Cancer Res. 1980;40:4335–4342
  35. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8–12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427–435
  36. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689

 Conflict of Interest: The following participants are associated with Sicel Technologies, Inc., the manufacturer of the implantable dosimeter used in the study: Charles W. Scarantino, M.D., Ph.D., is a cofounder of the company, medical director for the company, and member of the Board of Directors; Gloria P. Beyer, Ph.D., is an officer of the company; Robert D. Black, Ph.D., was an officer of the company during the study and a consultant for the company at the time of data analysis; Natasha Bolick is an employee of the company.

 The study analyzes the data obtained from a Food and Drug Administration–approved study protocol. The data used and presented in this research were collected, monitored, and managed in accordance with the FDA's adopted ICH Guideline for Good Clinical Practice and 21 CFR Parts 50, 54, 56, and 812 and 45 CFR Parts 160 and 164.

 Supported in part by NCI Grant R21CA 97859.

PII: S0360-3016(08)02465-6

doi: 10.1016/j.ijrobp.2008.05.058

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 597-604 , 1 October 2008

Article Tools

* Image Usage & Resolution